An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma.
Gilles A. Salles
Consultant or Advisory Role - Gilead Sciences; Janssen Research & Development; Roche
Honoraria - Mundipharma; Roche
Ajay K. Gopal
Research Funding - Janssen Research & Development
Peter Martin
Honoraria - Janssen Research & Development
Robert Marcus
No relevant relationships to disclose
Georg Hess
Honoraria - Janssen Research & Development
Pier Luigi Zinzani
No relevant relationships to disclose
Tahamtan Ahmadi
Employment or Leadership Position - Janssen Research & Development
Sen Hong Zhuang
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Ronald Levy
Consultant or Advisory Role - Janssen